SCHEDULE: Jeito Capital Discloses 7.8% Stake in Odyssey Therapeutics

Jeito II S.L.P. and associated entities have filed a Schedule 13D reporting a 7.8% beneficial ownership stake in Odyssey Therapeutics, Inc. following its recent IPO.

Summary

• Jeito II S.L.P. holds 3,690,145 shares of Odyssey Therapeutics, Inc. common stock.
• The stake represents 7.8% of the company's total outstanding shares.
• The position was established through the conversion of Series D preferred stock and warrants, plus a direct purchase of 1,388,888 shares at $18.00 per share during the IPO.
• The filing is a joint disclosure by Jeito II S.L.P., Jeito Capital SAS, Rafaele Tordjman, and Sabine Dandiguian.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral, routine disclosure of institutional ownership following an IPO, indicating stability in the shareholder base.

Positives

• The reporting persons are long-term investors with a significant 7.8% equity stake.
• Ksenija Pavletic, a General Partner at Jeito Capital, serves on the Board of Directors, providing direct oversight and influence.

Negatives

• The shares are subject to a 180-day lock-up agreement expiring in November 2026, limiting immediate liquidity for the reporting persons.

Risks

• Market volatility could impact the value of the investment.
• Future liquidity requirements or changes in business prospects may lead the reporting persons to dispose of shares.
• The investment is subject to the terms of a lock-up agreement and an Investors' Rights Agreement.

Future Outlook

The reporting persons intend to review their investment on a continuing basis and may acquire or dispose of shares depending on market conditions and the Issuer's business prospects.

Management Comments

• The reporting persons intend to review their investment in the Issuer on a continuing basis.
• The reporting persons may engage in discussions with the Board, management, or other stockholders regarding business, strategy, or governance.

Industry Context

StockSavvy.ai notes that this filing is standard for venture capital firms transitioning from private to public ownership in the biotech sector, signaling continued institutional support for Odyssey Therapeutics post-IPO.

Comparison to Industry Standards

• The 180-day lock-up period is standard practice for institutional investors following a biotech IPO.
• The presence of a board seat for a major investor is consistent with typical venture capital governance structures in early-stage public life sciences companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Indicates institutional confidence in the company's long-term prospects.
• Company: Maintains a stable, long-term oriented investor base.

Next Steps

• Reporting persons will continue to monitor their investment.
• Lock-up agreement expires 180 days after May 7, 2026.
• Registration rights under the Investors' Rights Agreement become exercisable 180 days after May 7, 2026.

Key Dates

Keywords

Odyssey Therapeutics, Jeito Capital, Schedule 13D, Biotech IPO, Institutional Ownership, Equity Stake